Minimally Invasive Surgery Symposium (MISS)
Metabolic & Endocrine Disease Summit (MEDS)
Cardiovascular and Respiratory Disease Summit (CARPS)
SDEF's Annual Women's & Pediatric Dermatology
Annual Coastal Dermatology Symposium
SDEF's Annual Las Vegas Dermatology Seminar & the Annual Psoriasis and Atopic Dermatology Forums
Annual Caribbean Dermatology Symposium
SDEF's Annual Hawaii Dermatology Seminar
Pain Care for Primary Care
Annual Digestive Diseases: New Advances Conference
Annual Perspectives in Rheumatic Diseases
CP/AACP Psychiatry Update Encore Presentation
Pelvic Anatomy & Gynecologic Surgery Symposium (PAGS)
Acute Leukemia Forum
International Platelet Symposium
CP/AACP Psychiatry Update
CP/AACP Focus on Neuropsychiatry
1.0 AMA PRA Category 1 Credits™
0.5 AMA PRA Category 1 Credit(s)™
1.0 AMA PRA Category 1 Credit(s)™
Patients who took at least 90% of their prescribed antimalarial doses were 39% less likely to develop type 2 diabetes mellitus.
Type 2 diabetes patients using SGLT2 inhibitors had significantly lower rates of gout than did those taking GLP1 agonists.
Lower body mass index topped both disease subtype and duration of illness as a predictor of low BMD and probable osteoporosis.
Each percentage increase in hemoglobin level was associated with a 7% increase in fracture risk.
LAS VEGAS – The agent and individual patient factors may affect the duration of treatment and the approach to resuming therapy.
BERLIN – In the first year after the initiation of continuous glucose monitoring, hypoglycemia episodes needing external help were significantly reduced.
Risk for type 2 diabetes mellitus and cardiovascular disease in adulthood can be calculated by measuring cardiorespiratory fitness in childhood.
There are no results under this Specialty.